2024
SWOG S2210: A phase II study of neoadjuvant carboplatin for localized, high-risk prostate cancer with germline BRCA1/2 mutations.
Cheng H, Callis S, Lin D, Yu E, Dorff T, Kase A, Tangen C, Petrylak D, Lerner S. SWOG S2210: A phase II study of neoadjuvant carboplatin for localized, high-risk prostate cancer with germline BRCA1/2 mutations. Journal Of Clinical Oncology 2024, 42: tps354-tps354. DOI: 10.1200/jco.2024.42.4_suppl.tps354.Peer-Reviewed Original ResearchPathological complete responseHigh-risk diseaseNeoadjuvant carboplatinRadical prostatectomyProstate cancerComplete responseCarriers of germline pathogenic variantsRate of pathological complete responseHigh-risk prostate cancerGermline BRCA1/2 mutationsPlatinum-based regimensBiochemical recurrence-freeMetastatic prostate cancerPhase II studyCurative intent treatmentGermline genetic testingGermline pathogenic variantsMonitoring of recurrenceFDA-approved optionsLate-stage diseaseGBRCA1/2mRecurrence-freeBRCA1/2 mutationsMetastasis-freeOverall survival
2022
Does perceived stigma or shame affect stage of presentation in Iraqi Kurdish women diagnosed with breast cancer?
Chagpar A, Qader S, Baqri M, Khoshnood K, Ahmed H. Does perceived stigma or shame affect stage of presentation in Iraqi Kurdish women diagnosed with breast cancer? Journal Of Clinical Oncology 2022, 40: e18680-e18680. DOI: 10.1200/jco.2022.40.16_suppl.e18680.Peer-Reviewed Original ResearchStage 1 diseaseBreast cancerStage diseaseStage 1 breast cancerHigher stage diseaseLate-stage diseaseStage of presentationCancer Stigma ScaleMonthly household incomeBCSS scoreMost patientsCancer patientsBreast centerPatientsStigma ScaleFeelings of shameFeelings of stigmaCancerDiseaseWomenPossible scoreMarital statusIraqi womenDiagnosisStage 1Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer
Glass E, Hoover A, Bullock K, Madden M, Reinfeld B, Harris W, Parker D, Hufnagel D, Crispens M, Khabele D, Rathmell W, Rathmell J, Wilson A, Giorgio T, Yull F. Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer. BMC Cancer 2022, 22: 497. PMID: 35513776, PMCID: PMC9074180, DOI: 10.1186/s12885-022-09612-2.Peer-Reviewed Original ResearchConceptsTumor-associated macrophagesAnti-tumor immunityOvarian cancerConsecutive days' treatmentTumor burdenMouse modelSolid tumorsImmunosuppressive tumor-associated macrophagesAnti-tumor phenotypeLate-stage diseaseClear therapeutic effectImmune cell compositionImmunosuppressive tumor microenvironmentM1 macrophage polarizationStrong translational potentialOvarian cancer modelFuture clinical studiesNF-κB alphaOvarian cancer progressionHigh response rateNF-κB activityEvidence of toxicityNuclear factor-kappaBInducible transgenic miceID8 model
2021
Extranodal Head and Neck Mantle Cell Lymphoma: Characteristics, Treatment, and Survival
Breen CT, Chao J, Mehra S, Kohli N. Extranodal Head and Neck Mantle Cell Lymphoma: Characteristics, Treatment, and Survival. Annals Of Otology Rhinology & Laryngology 2021, 131: 412-419. PMID: 34137303, DOI: 10.1177/00034894211025171.Peer-Reviewed Original ResearchConceptsMantle cell lymphomaExtranodal mantle cell lymphomaCumulative incidenceOverall survivalCell lymphomaEnd Results 18 registriesStage IV diseaseEarly-stage diseaseCause-specific hazards modelLate-stage diseaseProportion of casesSignificant differencesExtranodal headChemoradiation therapyCommon subsiteDisease characteristicsCommon siteAnatomic sitesPrimary headRadiation therapyCommon treatmentOral cavityHazards modelStage IIIStage I
2020
Challenges in the Diagnosis and Treatment of Lyme Disease
Schoen R. Challenges in the Diagnosis and Treatment of Lyme Disease. Current Rheumatology Reports 2020, 22: 3. PMID: 31912251, DOI: 10.1007/s11926-019-0857-2.Peer-Reviewed Original ResearchConceptsTreatment of Lyme diseaseClinical featuresCourse of oral antibiotic therapyOral antibiotic therapyLate-stage manifestationLate-stage diseaseLyme diseaseAntibiotic therapyCausative organismTreatment strategiesClinical expressionLyme arthritisImpact of Lyme diseaseDiagnosisDiseasePatientsTreatmentVector-borne illnessStrains of Borrelia burgdorferiLymeWell-characterizedMorbidityTherapyFindingsIt
2019
Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune Microenvironment
Mills B, Connolly K, Ye J, Murphy J, Uccello T, Han B, Zhao T, Drage M, Murthy A, Qiu H, Patel A, Figueroa N, Johnston C, Prieto P, Egilmez N, Belt B, Lord E, Linehan D, Gerber S. Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune Microenvironment. Cell Reports 2019, 29: 406-421.e5. PMID: 31597100, PMCID: PMC6919969, DOI: 10.1016/j.celrep.2019.08.095.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyMultiple preclinical mouse modelsPancreatic ductal adenocarcinoma patientsEffective neoadjuvant therapyAdvanced metastatic diseaseStereotactic body radiationDuctal adenocarcinoma patientsLate-stage diseaseInterferon-gamma productionBody radiation therapySystemic tumor immunityPreclinical mouse modelsNeoadjuvant approachNeoadjuvant therapyLiver metastasesMetastatic diseaseCD8 TTumor immunityAdenocarcinoma patientsImmune microenvironmentTumor reductionMS administrationTherapy resultsPancreatic tumorsGamma productionHuman Ovarian Cancer Tumor Formation in Severe Combined Immunodeficient (SCID) Pigs
Boettcher AN, Kiupel M, Adur MK, Cocco E, Santin AD, Bellone S, Charley SE, Blanco-Fernandez B, Risinger JI, Ross JW, Tuggle CK, Shapiro EM. Human Ovarian Cancer Tumor Formation in Severe Combined Immunodeficient (SCID) Pigs. Frontiers In Oncology 2019, 9: 9. PMID: 30723704, PMCID: PMC6349777, DOI: 10.3389/fonc.2019.00009.Peer-Reviewed Original ResearchPreclinical animal modelsSCID pigsOvarian carcinomaAnimal modelsEar tissueLate-stage diseaseLethal gynecologic malignancyOvarian cancer researchImmunodeficient pigsGynecologic malignanciesCarcinoma cell linesImmunohistochemical phenotypeCytokeratin 7Ovarian cancerXenotransplantation modelNeck musclesOrthotopic modelTumor massOvCa cellsPapillary carcinoma cell lineCarcinomaControl pigsClaudin-4Claudin-3Tumors
2018
Changing prognosis of oral cancer: An analysis of survival and treatment between 1973 and 2014
Cheraghlou S, Schettino A, Zogg CK, Judson BL. Changing prognosis of oral cancer: An analysis of survival and treatment between 1973 and 2014. The Laryngoscope 2018, 128: 2762-2769. PMID: 30194691, DOI: 10.1002/lary.27315.Peer-Reviewed Original ResearchConceptsOral cavity cancerLate-stage diseaseAdjuvant therapyOral cancerEnd Results 9 registriesCox survival regressionHigher nodal yieldsNational Cancer DatabaseEarly-stage diseaseKaplan-Meier analysisRetrospective database analysisAnalysis of survivalAdjuvant chemoradiotherapyNodal yieldAdult patientsNeck dissectionRetrospective studyCancer DatabasePrognosisPatientsCancerDiseaseDatabase analysisSurvival regressionChemoradiotherapyAdjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database
Cheraghlou S, Kuo P, Mehra S, Agogo GO, Bhatia A, Husain ZA, Yarbrough WG, Burtness BA, Judson BL. Adjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database. Head & Neck 2018, 40: 1343-1355. PMID: 29756412, DOI: 10.1002/hed.24984.Peer-Reviewed Original ResearchConceptsNational Cancer Data BaseLate-stage diseaseAdjuvant treatmentSalivary gland cancerAdverse featuresAdjuvant radiotherapyImproved survivalGland cancerMajor salivary gland cancerAddition of chemotherapyNational Cancer DatabaseAdjuvant therapySurvival benefitRetrospective studyCancer DatabaseImproved outcomesCancer casesPatientsChemotherapyDiseaseTreatmentRadiotherapySurvivalCancerTherapy
2017
Treatment guidelines and patterns of care in oral cavity squamous cell carcinoma: Primary surgical resection vs. nonsurgical treatment
Fujiwara RJT, Burtness B, Husain ZA, Judson BL, Bhatia A, Sasaki CT, Yarbrough WG, Mehra S. Treatment guidelines and patterns of care in oral cavity squamous cell carcinoma: Primary surgical resection vs. nonsurgical treatment. Oral Oncology 2017, 71: 129-137. PMID: 28688680, DOI: 10.1016/j.oraloncology.2017.06.013.Peer-Reviewed Original ResearchConceptsOral cavity squamous cell carcinomaNational Cancer Data BaseLate-stage diseasePrimary nonsurgical treatmentOral cavity malignancyNonsurgical treatmentSquamous cell carcinomaOverall survivalSurgical resectionCell carcinomaTreatment modalitiesNational Comprehensive Cancer Network Clinical Practice GuidelinesAcademic/research programMultimodality clinical trialsDefinitive radiation therapyImproved overall survivalDecreased overall survivalPrimary surgical resectionOral cavity cancerNon-randomized natureClinical practice guidelinesPatterns of careNon-white raceProportional hazards modelBinary logistic regression
2016
Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer
Fu Y, Biglia N, Wang Z, Shen Y, Risch HA, Lu L, Canuto EM, Jia W, Katsaros D, Yu H. Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer. Gynecologic Oncology 2016, 143: 642-649. PMID: 27667152, PMCID: PMC5507336, DOI: 10.1016/j.ygyno.2016.09.021.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdenocarcinoma, Clear CellAdultAgedAged, 80 and overCarcinoma, EndometrioidCarcinoma, Ovarian EpithelialHumansMiddle AgedNeoplasm GradingNeoplasm StagingNeoplasms, Cystic, Mucinous, and SerousNeoplasms, Glandular and EpithelialOvarian NeoplasmsPrognosisProportional Hazards ModelsReverse Transcriptase Polymerase Chain ReactionRNA, Long NoncodingYoung AdultConceptsEpithelial ovarian cancerOvarian cancerStage diseasePatient survivalGrade tumorsASAP1-IT1Survival associationsLong non-coding RNAsCox proportional hazards regression modelPrimary epithelial ovarian cancerProportional hazards regression modelsTumor samplesFresh frozen tumor samplesHigh expressionEarly-stage diseaseFavorable overall survivalLate-stage diseaseHazards regression modelsLow-grade tumorsHigh-grade tumorsOvarian cancer progressionNon-coding RNAsImportant biological actionsOverall survivalPoor prognosis
2015
Improved prognosis for patients with oral cavity squamous cell carcinoma: Analysis of the National Cancer Database 1998–2006
Schwam ZG, Judson BL. Improved prognosis for patients with oral cavity squamous cell carcinoma: Analysis of the National Cancer Database 1998–2006. Oral Oncology 2015, 52: 45-51. PMID: 26553389, DOI: 10.1016/j.oraloncology.2015.10.012.Peer-Reviewed Original ResearchConceptsOral cavity squamous cell carcinomaLate-stage diseaseThree-year overall survivalEarly-stage diseaseEarly-stage patientsStage diseaseSquamous cell carcinomaStage patientsNeck dissectionOverall survivalCell carcinomaObserved survival improvementNational Cancer DatabaseRetrospective cohort studyHigh-volume centersNegative surgical marginsAdvanced-stage patientsLarge administrative databaseAdjuvant chemoradiationOCSCC patientsAdjuvant therapyCohort studyImproved survivalSurgical marginsSurvival improvementThe Evolving Landscape of HER2 Targeting in Breast Cancer
Moasser MM, Krop IE. The Evolving Landscape of HER2 Targeting in Breast Cancer. JAMA Oncology 2015, 1: 1154. PMID: 26204261, DOI: 10.1001/jamaoncol.2015.2286.Peer-Reviewed Original ResearchConceptsTreatment of HER2Breast cancerImmunologic effectorsHER2 targetingSubstantial single-agent activityHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Value of HER2Lines of therapyGrowth factor receptor 2Single-agent activityLate-stage diseaseStage of diseaseUseful predictive biomarkerHER2 inhibitor lapatinibFactor receptor 2Variety of cytotoxicModest efficacyTrastuzumab resistancePredictive biomarkersCell surface expressionImmunologic activityInhibitor lapatinibReceptor 2Advanced stageTreatment of Scarring Alopecia in Discoid Variant of Chronic Cutaneous Lupus Erythematosus With Tacrolimus Lotion, 0.3%
Milam EC, Ramachandran S, Franks AG. Treatment of Scarring Alopecia in Discoid Variant of Chronic Cutaneous Lupus Erythematosus With Tacrolimus Lotion, 0.3%. JAMA Dermatology 2015, 151: 1113-1116. PMID: 26039539, DOI: 10.1001/jamadermatol.2015.1349.Peer-Reviewed Original ResearchConceptsDiscoid lupus erythematosusCutaneous lupus erythematosusLupus erythematosusScarring alopeciaHair regrowthChronic cutaneous lupus erythematosusOral antimalarial therapyPermanent scarring alopeciaAutoimmune inflammatory disorderFirst-line therapyLate-stage diseasePotential therapeutic optionAlcohol baseChronic variantsDiscoid variantOral antimalarialsIntralesional corticosteroidsDLE lesionsTherapeutic optionsInflammatory disordersAntimalarial therapyPermanent scarringRetrospective analysisLesion severityIrreversible alopeciaDetection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas
Wang Y, Springer S, Mulvey CL, Silliman N, Schaefer J, Sausen M, James N, Rettig EM, Guo T, Pickering CR, Bishop JA, Chung CH, Califano JA, Eisele DW, Fakhry C, Gourin CG, Ha PK, Kang H, Kiess A, Koch WM, Myers JN, Quon H, Richmon JD, Sidransky D, Tufano RP, Westra WH, Bettegowda C, Diaz LA, Papadopoulos N, Kinzler KW, Vogelstein B, Agrawal N. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Science Translational Medicine 2015, 7: 293ra104. PMID: 26109104, PMCID: PMC4587492, DOI: 10.1126/scitranslmed.aaa8507.Peer-Reviewed Original ResearchConceptsNeck squamous cell carcinomaOral cavity cancerSquamous cell carcinomaTumor DNACell carcinomaOral cavityDetection of HNSCCLate-stage diseaseFraction of patientsPlasma of patientsTumor-specific DNASomatic mutationsHNSCC patientsPatientsValuable biomarkerClinical diagnosisHuman papillomavirus genesCancerSalivaCarcinomaRecurrenceBiomarkersHPVOropharynxHNSCC
2014
cAMP-PKA phosphorylation of tau confers risk for degeneration in aging association cortex
Carlyle BC, Nairn AC, Wang M, Yang Y, Jin LE, Simen AA, Ramos BP, Bordner KA, Craft GE, Davies P, Pletikos M, Šestan N, Arnsten AF, Paspalas CD. cAMP-PKA phosphorylation of tau confers risk for degeneration in aging association cortex. Proceedings Of The National Academy Of Sciences Of The United States Of America 2014, 111: 5036-5041. PMID: 24707050, PMCID: PMC3977284, DOI: 10.1073/pnas.1322360111.Peer-Reviewed Original ResearchConceptsNeurofibrillary tanglesAssociation cortexAlzheimer's diseaseSpine apparatusPhosphorylated tauPattern of neurodegenerationLate-stage diseaseHigh-risk factorsNormal aged miceGenetic rodent modelsPrefrontal association cortexPrimary sensory cortexPrimary visual cortexAge-related increasePyramidal neuronsCorticocortical connectionsAged miceRisk factorsGlutamate synapsesSpine synapsesSelective vulnerabilityRodent modelsDendritic spinesSensory cortexProtein kinase phosphorylation
2013
Pediatric thymomas: report of two cases and comprehensive review of the literature
Fonseca AL, Ozgediz DE, Christison-Lagay ER, Detterbeck FC, Caty MG. Pediatric thymomas: report of two cases and comprehensive review of the literature. Pediatric Surgery International 2013, 30: 275-286. PMID: 24322668, DOI: 10.1007/s00383-013-3438-x.Peer-Reviewed Original ResearchConceptsStage diseaseSurgical excisionRare pediatric malignancyMasaoka stage IEarly-stage diseaseSlight male predominanceTreatment of thymomaLate-stage diseaseMulti-institutional studyPediatric thymomaAdjuvant therapyClinical courseMyasthenia gravisPrognostic factorsMale predominanceIndolent behaviorPediatric malignanciesRare tumorCase reportReference listsStage IIIThymomaStage IStage IVPubMed database
2012
Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence
Schwarz R, Zelenev A, Bruce RD, Altice FL. Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence. Journal Of Substance Use And Addiction Treatment 2012, 43: 451-457. PMID: 22534003, PMCID: PMC3419304, DOI: 10.1016/j.jsat.2012.03.008.Peer-Reviewed Original ResearchConceptsBuprenorphine maintenance treatmentHealthcare utilizationED utilizationEmergency department usageOpioid-dependent patientsEmergency department utilizationLate-stage diseaseTreatment-seeking patientsBuprenorphine treatmentChart reviewPerson yearsED useMaintenance treatmentOpioid dependenceDependent patientsPrimary careHospitalizationDrug usersNegative binomial regressionBinomial regressionPatientsComparison of timeTreatmentAverage lengthStayLoss of expression of the cancer stem cell marker aldehyde dehydrogenase 1 correlates with advanced-stage colorectal cancer
Hessman C, Bubbers E, Billingsley K, Herzig D, Wong M. Loss of expression of the cancer stem cell marker aldehyde dehydrogenase 1 correlates with advanced-stage colorectal cancer. The American Journal Of Surgery 2012, 203: 649-653. PMID: 22405917, PMCID: PMC4285581, DOI: 10.1016/j.amjsurg.2012.01.003.Peer-Reviewed Original ResearchConceptsAldehyde dehydrogenase 1Cancer stem cellsClinical outcomesLoss of expressionCSC marker aldehyde dehydrogenase 1Advanced stage colorectal cancerMarker expressionMetastatic CRC samplesAmerican Joint CommitteeLate-stage diseaseColorectal cancer progressionEffective therapeutic targetNonmetastatic CRCMetastatic diseaseEarly CRCALDH1 expressionColorectal cancerCancer stageCRC tumorsCRC samplesTumors variesDisease prognosisNonmetastatic tumorsTherapeutic targetJoint Committee
2011
Neuropsychiatric symptoms in Alzheimer's disease
Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J, Cedarbaum J, Brashear R, Miller DS. Neuropsychiatric symptoms in Alzheimer's disease. Alzheimer's & Dementia 2011, 7: 532-539. PMID: 21889116, PMCID: PMC3299979, DOI: 10.1016/j.jalz.2011.05.2410.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply